

## **Incidence and Trends in Ischemic Stroke and Mortality in Patients with and Without Type 2 Diabetes in Taiwan 2000-2018**

### **Short title: Trends of Ischemic Stroke in Diabetes in Taiwan**

Fu-Shun Yen, MD; James Cheng-Chung Wei, PhD; Tzu-Ju Hsu, MS; Ying-Hsiu Shih, MS;  
Yun Kai Yeh, MD; Chih-Cheng Hsu, DrPH; Chii-Min Hwu, MD

### **Affiliations**

Dr. Yen's Clinic, Taoyuan, Taiwan (F.S.Y.), Department of Allergy, Immunology & Rheumatology, Chung Shan Medical University Hospital, Taichung City, Taiwan (J.C.C.W.), Institute of Medicine, Chung Shan Medical University, Taichung City, Taiwan (J.C.C.W.), Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan (J.C.C.W.), Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan (T.J.S., Y.H.S.), College of Medicine, China Medical University, Taichung City, Taiwan (T.J.S., Y.H.S.), Section of Endocrinology and Metabolism, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan (Y.K.Y., C.M.H.), Institute of Population Health Sciences, National Health Research Institutes, Miaoli County, Taiwan (C.C.H.), Department of Health Services Administration, China Medical University, Taichung, Taiwan (C.C.H.), Department of Family Medicine, Min-Sheng General Hospital, Taoyuan, Taiwan. (C.C.H.), National Center for Geriatrics and Welfare Research, National Health Research Institutes, Miaoli County, Taiwan (C.C.H.), Faculty of Medicine, National Yang-Ming Chiao Tung University School of Medicine, Taipei, Taiwan (C.M.H.).

Correspondence to Chih-Cheng Hsu, 35 Keyan Road, Zhunan, Miaoli County 35053, Taiwan.

Email: [cch@nhri.edu.tw](mailto:cch@nhri.edu.tw)

Chii-Min Hwu, No. 201, Sec. 2, Shipai Road, Beitou District, Taipei 11217, Taiwan. Email:

[chhwu@vghtpe.gov.tw](mailto:chhwu@vghtpe.gov.tw)

**The total word count of the manuscript (including Title Page, Abstract, Text,**

**References, Tables and Figures Legends): 6173**

**BACKGROUND:** Stroke has a significant impact on life expectancy, comparable to that of cardiovascular disease in Asia. We conducted this longitudinal study to examine the incidence of ischemic stroke and 30-day mortality among persons with and without type 2 diabetes (T2D). We also compared outcomes between those over and under 60 years and between men and women.

**METHODS:** We enrolled participants from the 2000 to 2018 National Health Insurance Research Database in Taiwan. Cox proportional-hazard models were used to examine the outcomes.

**RESULTS:** The incidence of in-hospital ischemic stroke in patients with and without T2D had significant reductions of 64.42% and 55.63%, respectively. The relative risk of stroke associated with diabetes remained significantly higher (2.01 to 2.33 times) than non-diabetes. The relative risk of stroke in patients under 60 with T2D was 2.56 to 4.36 times higher than in those without T2D. Between 2000 and 2018, there was a significant 83.24% and 88.55% reduction in the risk of 30-day mortality after stroke in patients with and without T2D. There was no significant increase in the risk of 30-day mortality in people with diabetes compared to those without diabetes. However, the relative risk of death from stroke in patients under 60 years with diabetes was 1.63 to 2.49 times higher than in those without diabetes.

**CONCLUSIONS:** This nationwide cohort study showed that the incidence of in-hospital ischemic stroke and 30-day mortality in patients with and without T2D exhibited a significant decreasing trend from 2000 to 2018. Patients with T2D had about twice the relative risk of ischemic stroke compared to those without T2D.

**Key Words:** ischemic stroke    type 2 diabetes    30-Day mortality

## INTRODUCTION

According to the Global Burden of Disease Study, stroke is the third leading cause of long-term disability and mortality worldwide.<sup>1</sup> There are 101.5 million cases of stroke worldwide, resulting in approximately 6.6 million cases of premature mortality with 125.4 million years of life lost and 17.7 million years of living with disability in the Global Burden of Disease Study 2019.<sup>2</sup> Therefore, stroke poses a severe threat of disability and death for adults. Furthermore, stroke risk varies between Asian countries and Western nations, with a higher risk to life and potential for death than cardiovascular disease.<sup>1,3,4</sup> Type 2 diabetes (T2D) is characterized by hyperglycemia and insulin resistance and is often associated with obesity, hypertension, and dyslipidemia, which increases patient susceptibility to cerebral atherosclerosis and stroke.<sup>5</sup> According to a meta-analysis and systemic review of 102 prospective studies, people with T2D have a 2.27 times higher risk of ischemic stroke than those without T2D.<sup>6</sup> Hyperglycemia can lead to impaired recanalization and decreased reperfusion in stroke patients, which results in further brain tissue damage and contributes to a worse prognosis for these patients.<sup>5</sup>

In recent years, some countries have advocated for proactive treatment of diabetes, hypertension, and hyperlipemia, leading to a notable decrease in the incidence and mortality rates of stroke in some countries.<sup>7,8</sup> However, the incidence of stroke remains unchanged in some countries, while in others, it has increased.<sup>9,10</sup> Furthermore, individuals with diabetes still have a significantly higher risk of stroke and stroke-related death than those without diabetes.<sup>6,11</sup> Moreover, a growing trend of young stroke patients (under 60 years) is noted worldwide.<sup>2,5,12</sup> As in Asian countries, stroke has a significant impact on life, comparable to that of cardiovascular disease.<sup>3</sup> However, most research on the relationship between diabetes and stroke has been conducted in Western countries, with relatively fewer studies conducted in Eastern countries. Furthermore, many studies do not delve into detailed data on diabetes

and stroke in younger individuals and recent mortality figures related to stroke. Therefore, we conducted this longitudinal study to investigate the incidence of ischemic stroke and within 30-day mortality rate among persons with and without T2D in Taiwan from 2000 to 2018. We also compared the stroke incidence and mortality risks between those over and under 60 and between males and females.

## **METHODS**

### **Data Sources**

The government of Taiwan initiated the National Health Insurance (NHI) program in 1995. This mandatory insurance program is largely funded by the government and employers, with only a minimal contribution required from individuals. By 2000, nearly 99% of Taiwan's 29 million people were enrolled in this insurance initiative. The National Health Insurance Research Database (NHIRD) maintains comprehensive medical records since 1995, documenting details such as patient age, date of birth, sex, place of residence, treatments received, and diagnostic data according to the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and ICD-10-CM codes. For this study, we methodically recruited individuals from the NHIRD.<sup>13</sup> The research was approved by the Research Ethics Committee of China Medical University and Hospital [CMUH111-REC2-109(CR-1)]. In accordance with privacy principles, all identifiable information from patients or care providers was encrypted before release, exempting this study from the requirement to obtain informed consent from participants by the Research Ethics Committee.

## **Study Design and Population**

This nationwide cohort study consecutively enrolled participants from the 2000-2004, 2005-2009, 2010-2014, and 2015-2018 NHIRDs to assess trends in ischemic stroke incidence among individuals with and without T2D. Identification of T2D was based on ICD-9/10-CM codes (Table S1), requiring at least 2 outpatient claims within 1 year or a single hospital admission record. The use of ICD codes for defining T2D is validated by previous studies, with an accuracy rate of 93.3%.<sup>14</sup>

We categorized individuals diagnosed with T2D as study cases, with the day of T2D diagnosis as the index date; those without a T2D diagnosis were control cases, with the same calendar year and corresponding index date for the study subject as the index date for the control cases. Follow-up began on the respective index dates and ended on December 31, 2019.

We excluded individuals identified with type 1 diabetes, those younger than 20 years or older than 100 years, those with missing data on age or sex, and those who had experienced a stroke or had been diagnosed with gestational diabetes mellitus before the index date.

## **Comorbidities**

This study assessed several potential confounding factors, including age, sex, obesity (a composite of overweight, obese, or severely obese), smoking habits, alcohol-related disorders, hypertension, dyslipidemia, coronary artery disease, heart failure, valvular heart disease, atrial fibrillation, chronic kidney disease, chronic obstructive pulmonary disease (COPD), liver cirrhosis, peripheral artery disease, history of venous thromboembolism, connective tissue disease, hyperthyroidism, and neoplasms. We also included the Charlson Comorbidity Index (CCI).<sup>15</sup> and Diabetes Complication Severity Index (DCSI)<sup>16</sup> scores to assess

participants' disease burden. We considered medications such as insulin, type and amount of antidiabetic and antihypertensive agents, statin, aspirin, ADP receptor inhibitors, vitamin K antagonists, and direct oral anticoagulants (Table 1).

### **Main Outcomes**

We examined the incidence of in-hospital ischemic stroke and 30-day mortality after stroke admission from 2000 to 2019. Previous studies conducted in Taiwan have shown the reliability and accuracy of ICD codes in identifying ischemic stroke cases.<sup>14,17</sup> Mortality data were confirmed using the National Death Registry. Incidence rates of ischemic stroke and associated 30-day mortality were calculated and compared between the study and control groups. Each participant was followed until the occurrence of one of the prespecified outcomes, withdrawal from the NHI system, or the end of the study on December 31, 2019, whichever occurred first.

### **Statistical Analyses**

We used 1:1 propensity score matching to adjust for year of recruitment, age, and sex between patients with and without T2D to improve comparability. The nearest neighbor technique was used for creating matched pairs, assuming that a p-value > 0.05 indicated balanced distributions in the study and control groups. For descriptive statistics, chi-squared tests and Student's t-tests were used to analyze the distribution of categorical and continuous variables, respectively. Crude and multivariate-adjusted Cox proportional hazards models, accompanied by robust sandwich standard error estimates, were used to assess the differential risk of outcomes between the study and control groups. Verification of the proportional hazards assumption was facilitated by Schoenfeld residuals and complementary log-log plots.

Results were expressed as hazard ratios (HRs) and 95% confidence intervals (CIs) for the study and control groups.

We used Cox proportional hazards models to analyze differences in the risk of ischemic stroke and 30-day mortality between men and women and between patients aged <60 and those aged  $\geq 60$ . We calculated the absolute and percent change in outcomes, the p-linear trend to see trend changes among these recruitment years, and the relative risk of outcomes between patients with and without T2D. We plotted figures to describe the relative risk of outcomes between patients (overall, male and female, age <60 and  $\geq 60$  years) with and without T2D among these recruiting years. We also performed a subgroup analysis to compare the risk of in-hospital ischemic stroke in patients under 60 years with T2D versus no T2D. A two-tailed p-value less than .05 was deemed statistically significant. All analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).

## **RESULTS**

### **Baseline Characteristics of the Study Population**

From the National Health Insurance Research Database for the years 2000-2004, 2005-2009, 2010-2014, and 2015-2018, we individually included 93,062, 58,641, 54,882, and 35,929 patients, respectively. Using propensity score matching for sex, age, and year of enrollment, we identified 242,514 pairs of patients with and without type 2 diabetes. Both groups showed excellent matching for age and sex (Table 1,  $p > 0.05$ ). In the matched cohort, 45.52% were female, the mean age was 54.23 years, and the mean follow-up for this study was 9.2 years.

### **Trend of Ischemic Stroke**



Between 2000 and 2018, the incidence of in-hospital ischemic stroke in patients with and without T2D had significant reductions of 64.42% and 55.63%, respectively. However, the relative risk of stroke associated with diabetes remained significantly higher (2.01 to 2.33 times) than that for non-diabetes (Table 2, Figure 1). Men had a higher risk of ischemic stroke than women. The relative risk of stroke was the same for patients with T2D (male or female) and those without T2D. However, from 2015 to 2018, there was a slight increase in the relative risk of stroke (relative risk = 2.86) for women with T2D compared to those without T2D.

People with diabetes aged 60 years and older have a 1.51 to 2.02 times higher relative risk of stroke than people without diabetes. Conversely, people under 60 with diabetes have a more profound (ranging from 2.56 to 4.36 times) higher relative risk of stroke than those without diabetes. Nevertheless, between 2000 and 2018, the incidence of stroke associated with diabetes and non-diabetes in people under 60 decreased by 65.62% and 50.51%, respectively, resulting in a significant downward trend in the relative risk of stroke for people under 60 with diabetes compared to those without diabetes (Figure 1).

Among patients under 60, patients with diabetes between 18-39 years have a significantly higher relative risk of ischemic stroke than non-diabetics than those in the 40-59 age group. Female with diabetes have a significantly higher relative risk of ischemic stroke compared to non-diabetics than their male counterparts (Table S2).

### **30-Day Mortality Rate**

Between 2000 and 2018, there was a significant decrease in the 30-day mortality rate after stroke in patients with and without T2D, with a reduction of 83.24% and 88.55%, respectively, and no significantly higher risk of death from stroke in people with diabetes compared to those without diabetes. The risk of death from stroke was similar for men and

women. However, there was an abrupt increase in the relative risk of death for women with T2D compared to women without T2D from 2015 to 2018. Among those aged 60 and older, patients with diabetes had the same or even lower relative risk of death from stroke compared to non-diabetics. However, those under 60 with diabetes had a 1.63 to 2.49 times higher relative risk of dying from stroke than their non-diabetic counterparts (Table 3, Figure 2).

## DISCUSSION

From 2000 to 2018, the incidence rate of in-hospital ischemic stroke has shown a significantly decreasing trend in patients with T2D and those without T2D in Taiwan. However, people with T2D still have a significantly higher risk of stroke than those without T2D, which is particularly notable for people under 60 with T2D, who have a higher risk of stroke than those without T2D. Patients with and without T2D in Taiwan experienced a significant decrease in 30-day mortality after ischemic stroke from 2000 to 2018. Patients under 60 with T2D have a higher risk of dying within 30 days of stroke than those without T2D. However, people over 60 with T2D have a similar or slightly lower risk of 30-day mortality than those without T2D.

In recent decades, the lifetime risk of stroke has declined in some high-income countries. However, the global lifetime risk of stroke continues to rise, possibly due to an aging population and increased incidence of metabolic diseases.<sup>4</sup> People with diabetes have twice the risk of ischemic stroke than those without diabetes.<sup>5,6</sup> In many countries, the risk of ischemic stroke from diabetes has decreased.<sup>7,18-23</sup> However, it remains about the same in some countries,<sup>9</sup> and in others, it has increased.<sup>11</sup> The varying trends in the incidence of ischemic stroke in different countries may be related to different definitions of diabetes and stroke, the control of risk factors, and differences in environmental and genetic factors.<sup>21</sup> In Taiwan, we observed a notable decline in the incidence of ischemic stroke from 2000 to 2018

in individuals with T2D and those without T2D. However, the decline was slightly more pronounced in individuals with diabetes than in those without diabetes. Nevertheless, people with diabetes still have more than twice the risk of having a stroke than people without diabetes. The decline in the incidence rate of ischemic stroke may be related to improved control of blood glucose, blood pressure, and cholesterol levels in recent years in Taiwan.<sup>24,25</sup>

Men have a higher risk of stroke than women in Taiwan. However, the relative risk of stroke in people with diabetes compared to those without diabetes and the declining trend is consistent for both men and women, in line with the overall population trend. This finding is consistent with the results of the Korea<sup>20</sup> and Scotland<sup>21</sup> studies. Because of younger age, people under 60 have a lower incidence of ischemic stroke than those over 60. However, people with diabetes under 60 have a significantly higher risk of stroke (ranging from 2.56 to 4.36 times) than those without diabetes. This finding is consistent with previous studies.<sup>5,6,20,22</sup> However, from 2000 to 2018, the decline in stroke incidence rate increased in people with diabetes under 60 compared to those without diabetes. Therefore, in Taiwan, the relative risk of experiencing an ischemic stroke has gradually decreased among individuals under 60 with diabetes compared to those without the disease.

Diabetes can worsen the prognosis for patients with stroke by increasing the likelihood of disability and even increasing the mortality rate from stroke.<sup>5</sup> In Taiwan, from 2000 to 2018, there has been a significant improvement in the 30-day mortality rate for stroke in individuals with and without diabetes, probably due to the implementation of the acute stroke care program in Taiwan in recent years, which includes the use of thrombolytic treatments, improved management of severe strokes, and higher identification of minor strokes.<sup>26</sup> Diabetes does not appear to have a higher stroke mortality rate than non-diabetes, consistent with the results of some previous studies.<sup>27-29</sup> The 30-day mortality rate is similar for men and women. However, between 2015 and 2018, there was a sudden increase in the relative

risk of stroke mortality in women with diabetes compared to women without diabetes. The reason for this is unclear. Individuals over 60 with diabetes have the same or a lower relative risk of stroke mortality compared to those without diabetes. However, people under 60 with diabetes still have a 1.63 to 2.49 times higher relative risk of stroke mortality than those without diabetes. We should work to improve the management of stroke in people under 60 with diabetes and women to reduce mortality.

Our study has some strengths and clinical implications. First, the Taiwan National Health Insurance Research Database covers the medical records of 99% of the population, which can help reduce selection bias. The study uses a nationwide database, an excellent tool for monitoring national trends in stroke incidence and related mortality. As this database is linked to the National Death Registry, the observations on the risk of stroke mortality are relatively reliable. Second, we observe that individuals under 60 with T2D have a significantly higher relative risk of ischemic stroke and a higher 30-day mortality rate than those without T2D. Therefore, we should encourage people under 60 with diabetes to increase physical activity levels, reduce obesity, stop smoking, avoid excessive alcohol consumption, and maintain optimal blood glucose, blood pressure, and cholesterol levels. Using medications such as pioglitazone or glucagon-like peptide-1 receptor agonists (GLP-1 RA) to manage diabetes may be a proactive approach to prevent stroke development and improve prognosis.<sup>30,31</sup>

This study has several limitations. First, the dataset does not include information on blood pressure, glucose, hemoglobin A1C, biochemical results, medical images, and echocardiograms, which are essential for proper diagnosis and assessment of T2D, hypertension, and stroke. Nevertheless, we used ICD codes to identify these conditions, a method validated with good accuracy in previous studies.<sup>14,17</sup> The lack of details on blood pressure and glucose levels implies that we could not assess treatment progress or measure

the severity of hypertension and diabetes in the study. However, to reduce the potential confounding effects of hypertension and T2D, we adjusted for the type and number of antihypertensive and antidiabetic medications used in our multivariable analyses. Second, our administrative dataset does not include details of family history, physical activity, and eating habits. Nevertheless, we included important factors such as age, sex, comorbidities, and use of antidiabetic, antihypertensive, and anticoagulant medications to adjust for multivariable analyses when comparing the study and control groups. Third, the participants in this study are predominantly Taiwanese; therefore, the results may not directly apply to other ethnic groups. However, they serve as a valuable source of information on stroke data in the Eastern population. Finally, this cohort study inherently contains some unknown confounders. Therefore, the results can only indicate associations and not establish causal relationships.

## **CONCLUSIONS**

This nationwide population-based cohort study showed that from 2000 to 2018, the incidence rate of ischemic stroke exhibited a significant decreasing trend in patients with T2D and those without T2D in Taiwan. However, patients with T2D still have a significantly higher risk of ischemic stroke than those without T2D, which is particularly notable for patients under 60 with T2D, who have a higher risk of stroke than those without T2D. Patients with and without T2D in Taiwan showed a significant decrease in the 30-day mortality rate after stroke from 2000 to 2018. Patients younger than 60 with T2D have a higher risk of 30-day mortality than those without T2D. We should encourage patients under 60 with T2D to adopt a healthy lifestyle and optimize the management of diabetes, hypertension, and dyslipidemia to reduce the risk of ischemic stroke and mortality.

## **Abbreviations**

COPD chronic obstructive pulmonary disease

CCI Charlson comorbidity Index

DCSI diabetes complications severity index

GLP-1 RA glucagon-like peptide 1 receptor agonist; T2D: type 2 diabetes.

## **Disclosure**

The authors declare no competing interests.

## **Source of Funding**

This study is supported in part by Taiwan Ministry of Health and Welfare Clinical Trial Center (MOHW112-TDU-B-212-144004), China Medical University Hospital (DMR-111-105; DMR-112-087), Taipei Veterans General Hospital (V111C-188, V112C-164, V113C-166), and National Science and Technology Council, R.O.C. (MOST 110-2314-B-075-027-MY3).

## **Acknowledgments**

We are grateful to Health Data Science Center, China Medical University Hospital, Szu-Yuan Research Foundation of Internal Medicine, and Y.L. Lin Hung Tai Education Foundation for providing administrative, technical and funding support. The funders had no role in the study design, data collection and analysis, the decision to publish, or preparation of the manuscript. No additional external funding was received for this study.

## **Supplemental Material**

### **Tables S1–S2**

## REFERENCES

1. Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, Abbasi-Kangevari M, Abbastabar H, Abd-Allah F, Abdelalim A, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet*. 2020;396:1204–1222.
2. GBD 2019. Institute for health metrics and evaluation, global health data exchange, global burden of disease study 2019 (GBD 2019) data resources, GBD results tool, terms and conditions. <http://ghdx.healthdata.org/gbd-results-tool>. Accessed 25 June 2023.
3. Lee M, Wu YL, Ovbiagele B. Trends in incident and recurrent rates of first-ever ischemic stroke in Taiwan between 2000 and 2011. *J Stroke*. 2016;18:60–65.
4. GBD 2016 Lifetime Risk of Stroke Collaborators. Global, regional, and country-specific lifetime risks of stroke, 1990 and 2016. *N Engl J Med*. 2018;379:2429–2437.
5. Luitse MJ, Biessels GJ, Rutten GE, Kappelle LJ. Diabetes, hyperglycaemia, and acute ischaemic stroke. *Lancet Neurol*. 2012;11:261–271.
6. Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. *Lancet*. 2010;375:2215–2222.
7. Gregg EW, Li Y, Wang J, Rios Burrows N, Ali MK, Rolka D, Williams DE, Geiss L. Changes in diabetes-related complications in the United States, 1990-2010. *N Engl J Med*. 2014;370:1514–1523.



8. Gu Q, Burt VL, Dillon CF, Yoon S. Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the national health and nutrition examination survey, 2001 to 2010. *Circulation*. 2012;126:2105–2114.
9. Fang M, Selvin E. Thirty-year trends in complications in US adults with newly diagnosed type 2 diabetes. *Diabetes Care*. 2021;44:699–706.
10. Muñoz-Rivas N, Méndez-Bailón M, Hernández-Barrera V, de Miguel-Yanes JM, Jimenez-Garcia R, Esteban-Hernandez J, Jimenez-Trujillo I, Alvaro-Meca A, Carrasco-Garrido P, et al. Time trends in ischemic stroke among type 2 diabetic and non-diabetic patients: analysis of the Spanish national hospital discharge data (2003-2012). *PLoS One*. 2015;10:e0145535.
11. Hatzitolios AI, Didangelos TP, Zantidis AT, Tziomalos K, Giannakoulas GA, Karamitsos DT. Diabetes mellitus and cerebrovascular disease: which are the actual data? *J Diabetes Complicat*. 2009;23:283–296.
12. Scott CA, Li L, Rothwell PM. Diverging temporal trends in stroke incidence in younger vs older people: a systematic review and meta-analysis. *JAMA Neurol*. 2022;79:1036–1048.
13. Yen FS, Wei JC, Chiu LT, Hsu CC, Hwu CM. Diabetes, hypertension, and cardiovascular disease development. *J Transl Med*. 2022;20:9.
14. Sung SF, Hsieh CY, Lin HJ, Chen YW, Yang YHK, Li CY. Validation of algorithms to identify stroke risk factors in patients with acute ischemic stroke, transient ischemic attack, or intracerebral hemorrhage in an administrative claims database. *Int J Cardiol*. 2016;215:277–282.

15. Meduru P, Helmer D, Rajan M, Tseng CL, Pogach L, Sambamoorthi U. Chronic illness with complexity: implications for performance measurement of optimal glycemic control. *J Gen Intern Med.* 2007;22:408–418.
16. Young BA, Lin E, Von Korff M, Simon G, Ciechanowski P, Ludman EJ, Everson-Stewart S, Kinder L, Oliver M, Boyko EJ, et al. Diabetes complications severity index and risk of mortality, hospitalization, and health care utilization. *Am J Manag Care.* 2008;14:15–23.
17. Hsieh CY, Chen CH, Li CY, Lai ML. Validating the diagnosis of acute ischemic stroke in a National Health Insurance claims database. *J Formos Med Assoc.* 2015;114:254–259.
18. Booth GL, Kapral MK, Fung K, Tu JV. Recent trends in cardiovascular complications among men and women with and without diabetes. *Diabetes Care.* 2006;29:32–37.
19. Norhammar A, Bodegård J, Nyström T, Thuresson M, Eriksson JW, Nathanson D. Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden, 2006-2013. *Diabetologia.* 2016;59:1692–1701.
20. Jung CH, Chung JO, Han K, Ko SH, Ko KS, Park JY, Taskforce Team of Diabetes Fact Sheet of the Korean Diabetes Association. Improved trends in cardiovascular complications among subjects with type 2 diabetes in Korea: a nationwide study (2006-2013). *Cardiovasc Diabetol.* 2017;16:1.
21. Read SH, McAllister DA, Colhoun HM, Farran B, Fischbacher C, Kerssens JJ, Leese GP, Lindsay RS, McCrimmon RJ, McGurnaghan S, et al. Incident ischaemic stroke and type 2 diabetes: trends in incidence and case fatality in Scotland 2004-2013. *Diabet Med.* 2018;35:99–106.

22. Gyldenkerne C, Kahlert J, Olesen KKW, Thrane PG, Sørensen HT, Thomsen RW, Thomsen RW, Maeng M. Twenty-year temporal trends in risk of ischemic stroke in incident type 2 diabetes: a Danish population-based cohort study. *Diabetes Care*. 2022;45:2144–2151.
23. Bambury N, O'Neill K, Buckley CM, Kearney PM. Trends in incidence of ischaemic stroke in people with and without diabetes in Ireland 2005-2015. *Diabet Med*. 2023;40:e15127.
24. Hsieh CY, Wu DP, Sung SF. Trends in vascular risk factors, stroke performance measures, and outcomes in patients with first-ever ischemic stroke in Taiwan between 2000 and 2012. *J Neurol Sci*. 2017;378:80–84.
25. Wang CY, Tu ST, Sheu WH, Chen IC, Chuang LM, Wu MS, Tu CJ. National survey of ABC (A1C, blood pressure, cholesterol) of Diabetes Health Promotion Institutes in Taiwan: 2002-2018. *J Formos Med Assoc*. 2018;117:952–954.
26. Hsieh FI, Lien LM, Chen ST, Bai CH, Sun MC, Tseng HP, Chen YW, Chen CH, Jeng JS, Tsai SY, et al. Get with the guidelines-stroke performance indicators: surveillance of stroke care in the Taiwan stroke registry: get with the guidelines-stroke in Taiwan. *Circulation*. 2010;122:1116–1123.
27. Lau LH, Lew J, Borschmann K, Thijs V, Ekinçi EI. Prevalence of diabetes and its effects on stroke outcomes: a meta-analysis and literature review. *J Diabetes Investig*. 2019;10:780–792.
28. Kamalesh M, Shen J, Eckert GJ. Long term postischemic stroke mortality in diabetes: a veteran cohort analysis. *Stroke*. 2008;39:2727–2731.

29. Koennecke HC, Belz W, Berfelde D, Endres M, Fitzek S, Hamilton F, Kreitsch P, Mackert BM, Nabavi DG, Nolte CH, et al. Factors influencing in-hospital mortality and morbidity in patients treated on a stroke unit. *Neurology*. 2011;77:965–972.
30. Yang YS, Chen HH, Huang CN, Hsu CY, Hu KC, Kao CH. GLP-1RAs for Ischemic stroke prevention in patients with type 2 diabetes without established atherosclerotic cardiovascular disease. *Diabetes Care*. 2022;45:1184–1192.
31. Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, Guarino PD, Lovejoy AM, Peduzzi PN, Conwit R, et al. Pioglitazone after ischemic stroke or transient ischemic attack. *N Engl J Med*. 2016;374:1321–1331.

## **Figure legend**

**Figure 1. Relative risk of in-hospital ischemic stroke in patients with and without T2D in Taiwan from 2000-2018.**

**Figure 2. Relative risk of 30-day mortality after stroke in patients with and without T2D in Taiwan from 2000-2018.**

**Table 1. Baseline Characteristics and Comorbidities in Persons with and Without T2D in Taiwan from 2000 to 2018**

Variables	2000-2004		2005-2009			2010-2014	2015-2018		Non-T2D		T2D		p-value
	(N= 93062)		(N=58641)			(N=54882)	(N=35929)		(N= 242514)		(N=242514)		
	n	%	n	%	n	%	n	%	n	%	n	%	
Sex													
female	43950	47.23	26880	45.84	24536	44.71	15311	42.61	110086	45.39	110677	45.64	0.0884
male	49112	52.77	31761	54.16	30346	55.29	20618	57.39	132428	54.61	131837	54.36	
Age													
18-40	8596	9.24	6440	10.98	6081	11.08	4097	11.40	25214	10.40	25214	10.40	0.3882
40-60	49134	52.80	32400	55.25	29903	54.49	18335	51.03	129327	53.33	129772	53.51	
60-80	35332	37.97	19801	33.77	18898	34.43	13497	37.57	87973	36.28	87528	36.09	
Mean (SD)	55.77	12.24	54.61	12.27	54.67	11.91	54.97	12.00	53.34	13.65	55.12	12.15	<0.001
Comorbidities													

Obesity	593	0.64	1272	2.17	1591	2.90	1308	3.64	1036	0.43	4764	1.96	<0.001
Smoking	31	0.03	817	1.39	1427	2.60	1586	4.41	2272	0.94	3861	1.59	<0.001
Alcohol-related disorders	1158	1.24	1811	3.09	2070	3.77	1311	3.65	2781	1.15	6350	2.62	<0.001
Hypertension	30507	32.78	28534	48.66	28613	52.14	18945	52.73	47228	19.47	106599	43.96	<0.001
Dyslipidemia	16579	17.82	21033	35.87	23866	43.49	16445	45.77	30227	12.46	77923	32.13	<0.001
Coronary artery disease	11401	12.25	11653	19.87	10674	19.45	6640	18.48	18754	7.73	40368	16.65	<0.001
Heart failure	2373	2.55	2540	4.33	2162	3.94	1344	3.74	3991	1.65	8419	3.47	<0.001
Heart valve disease	236	0.25	264	0.45	178	0.32	110	0.31	568	0.23	788	0.32	<0.001
Atrial fibrillation	4580	4.92	5590	9.53	5612	10.23	3707	10.32	10983	4.53	19489	8.04	<0.001
Chronic kidney disease	4722	5.07	4990	8.51	4951	9.02	3553	9.89	9998	4.12	18216	7.51	<0.001
COPD	8466	9.10	8864	15.12	8000	14.58	4906	13.65	20691	8.53	30236	12.47	<0.001
Liver cirrhosis	1496	1.61	1298	2.21	1148	2.09	739	2.06	2921	1.20	4681	1.93	<0.001

Peripheral artery disease	650	0.70	1149	1.96	1416	2.58	940	2.62	1996	0.82	4155	1.71	<0.001
Previous venous thromboembolism	84	0.09	132	0.23	165	0.30	103	0.29	295	0.12	484	0.20	<0.001
Connective tissue disease	7678	8.25	9630	16.42	9268	16.89	5816	16.19	19665	8.11	32392	13.36	<0.001
Hyperthyroidism	974	1.05	1403	2.39	1826	3.33	1243	3.46	3487	1.44	5446	2.25	<0.001
Neoplasms	2190	2.35	1928	3.29	2305	4.20	1832	5.10	8144	3.36	8255	3.40	0.3779
CCI													
1	89317	95.98	54777	93.41	50638	92.27	32779	91.23	230673	95.12	227511	93.81	<0.001
2	3229	3.47	3273	5.58	3635	6.62	2716	7.56	10352	4.27	12853	5.30	
≥3	516	0.55	591	1.01	609	1.11	434	1.21	1489	0.61	2150	0.89	
DCSI													
1	68916	74.05	34535	58.89	30107	54.86	18960	52.77	188871	77.88	152518	62.89	<0.001
2	12910	13.87	11329	19.32	11033	20.10	7141	19.88	28234	11.64	42413	17.49	



≥3	11236	12.07	12777	21.79	13742	25.04	9828	27.35	25409	10.48	47583	19.62	
Medication													
Metformin	11329	12.17	5385	9.18	5101	9.29	4547	12.66	-	-	26362	10.87	<0.001
Sulfonamides	16117	17.32	5821	9.93	3532	6.44	2054	5.72	-	-	27524	11.35	<0.001
TZD	811	0.87	593	1.01	397	0.72	232	0.65	-	-	2033	0.84	<0.001
DPP-4i	-	-	10	0.02	484	0.88	951	2.65	-	-	1445	0.60	<0.001
AGI	751	0.81	661	1.13	567	1.03	400	1.11	-	-	2379	0.98	<0.001
SGLT-2 inhibitors	-	-	-	-	-	-	65	0.18	-	-	65	0.03	<0.001
Number of oral antidiabetic drugs													
1	83505	89.73	54928	93.67	52115	94.96	33804	94.09	-	-	224352	92.51	<0.001
2	8561	9.20	3097	5.28	2162	3.94	1542	4.29	-	-	15362	6.33	
≥3	996	1.07	616	1.05	605	1.10	583	1.62	-	-	2800	1.15	
GLP1-RA	-	-	-	-	-	-	8	0.02	-	-	8	0.00	0.0047
Insulin	13903	14.94	15926	27.16	15971	29.10	10550	29.36	-	-	56350	23.24	<0.001

ACEI/ARB	17915	19.25	19605	33.43	20981	38.23	15144	42.15	30236	12.47	73645	30.37	<0.001
β-blockers	12871	13.83	16595	28.30	17474	31.84	11452	31.87	31768	13.10	58392	24.08	<0.001
Calcium-channel blockers	23812	25.59	25722	43.86	26358	48.03	17529	48.79	43723	18.03	93421	38.52	<0.001
Diuretics	15990	17.18	19146	32.65	18681	34.04	12005	33.41	34037	14.04	65822	27.14	<0.001
Number of antihypertensive drugs													
1	72195	77.58	33916	57.84	29316	53.42	18536	51.59	204010	84.12	153963	63.49	<0.001
2	11616	12.48	10418	17.77	10467	19.07	7304	20.33	21084	8.69	39805	16.41	
≥3	9251	9.94	14307	24.40	15099	27.51	10089	28.08	17420	7.18	48746	20.10	
Statin	5770	6.20	9889	16.86	12627	23.01	9668	26.91	13848	5.71	37954	15.65	<0.001
Aspirin	16311	17.53	18208	31.05	17328	31.57	11146	31.02	31380	12.94	62993	25.97	<0.001
ADP receptor inhibitors	184	0.20	756	1.29	980	1.79	891	2.48	1145	0.47	2811	1.16	<0.001
Vitamin K antagonists	415	0.45	516	0.88	540	0.98	397	1.10	1181	0.49	1868	0.77	<0.001
Direct oral	-	-	-	-	20	0.04	154	0.43	94	0.04	174	0.07	<0.001

anticoagulants													
----------------	--	--	--	--	--	--	--	--	--	--	--	--	--

Data are shown as n (%) or mean ± SD. T2D, type 2 diabetes; COPD, chronic obstructive pulmonary disease; PAOD, peripheral arterial occlusion disease; CCI, Charlson Comorbidity Index; DCSI, Diabetes Complications Severity Index; SGLT-2, sodium glucose cotransporter-2, GLP-1 RA, glucagon-like peptide-1 receptor agonist; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker. A p-value of >0.05 indicates a negligible difference between patients with T2D and non-T2D.

**Table 2. Event Rate and Relative Risk of Ischemic Stroke in Persons with and Without Type 2 Diabetes**

Variables	Year				Change		P-value linear trend
	2000-2004	2005-2009	2010-2014	2015-2018			
	IR (95% CI)	IR (95% CI)	IR (95% CI)	IR (95% CI)	Absolute change	Percent change	
Ischemic stroke							
No. of events/10,000 in T2D	102.50	58.78	45.88	38.52	-63.98	-62.42%	<0.0001

95% CI	(83.62, 124.37)	(44.73, 75.86)	(33.58, 61.22)	(27.33, 52.76)			
No. of events/10,000 in non-T2D	40.14	25.67	18.75	17.81	-22.33	-55.63%	<0.0001
95% CI	(28.70, 54.63)	(16.71, 37.70)	(11.24, 29.36)	(10.53, 28.22)			
RR (95%CI)	2.33(2.24, 2.41)***	2.01(1.88, 2.15)***	2.16(1.95, 2.39)***	2.16(1.72, 2.71)***			<0.0001
Sex							
Female							
No. of events/10,000 in T2D	88.48	49.01	34.18	30.38	-58.10	-65.66%	<0.0001
95% CI	(71.00, 108.94)	(36.26, 64.80)	(23.69, 47.72)	(20.56, 43.28)			
No. of events/10,000 in non-T2D	32.39	20.98	13.93	10.98	-21.41	-66.10%	<0.0001
95% CI	(22.21, 45.63)	(12.99, 32.08)	(7.60, 23.40)	(5.47, 19.65)			
RR (95%CI)	2.50(2.37, 2.64)***	2.01(1.80, 2.24)***	2.05(1.71, 2.40)***	2.86(1.86, 4.36)***			<0.0001

	2.65)***	2.24)***	2.46)***	4.40)***			
Male							
No. of events/10,000 in T2D	116.34	67.58	55.68	44.73	-71.61	-61.55%	<0.0001
95% CI	(96.16, 139.50)	(52.43, 85.73)	(42.02, 72.36)	(32.59, 59.90)			
No. of events/10,000 in non-T2D	48.00	29.82	22.73	22.84	-25.16	-52.42%	<0.0001
95% CI	(35.39, 63.64)	(20.10, 42.62)	(14.37, 34.19)	(14.45, 34.31)			
RR (95% CI)	2.22(2.12, 2.33)***	2.02(1.86, 2.19)***	2.21(1.95, 2.50)***	1.91(1.46, 2.49)***			<0.0001
Age, years							
<60							
No. of events/10,000 in T2D	67.63	36.87	30.92	23.25	-44.38	-65.62%	<0.0001
95% CI	(52.48, 85.79)	(25.95, 50.85)	(21.00, 43.91)	(14.78, 34.81)			

No. of events/10,000 in non-T2D	14.71	9.31	7.91	7.28	-7.43	-50.51%	<0.0001
95% CI	(8.18, 24.38)	(4.32, 17.49)	(3.40, 15.64)	(2.99, 14.80)			
RR (95%CI)	4.36(4.09, 4.65)***	3.46(3.07, 3.90)***	3.37(2.83, 4.03)***	2.56(1.68, 3.91)***			<0.0001
≥60							
No. of events/10,000 in T2D	179.74	108.61	76.37	64.99	-114.75	-63.84%	<0.0001
95% CI	(154.42, 208.02)	(89.15, 131.06)	(60.20, 95.53)	(50.16, 82.84)			
No. of events/10,000 in non-T2D	106.42	63.59	40.69	35.07	-71.35	-67.05%	<0.0001
95% CI	(87.17, 128.67)	(48.93, 81.26)	(29.16, 55.27)	(24.44, 48.76)			
RR (95%CI)	1.62(1.55, 1.69)***	1.51(1.39, 1.64)***	1.68(1.48, 1.91)***	2.02(1.54,2.65)* **			<0.0001

T2D, type 2 diabetes; IR, incidence rate (per 10 =100 person years); RR, relative risk.

\*\*\*  $p < 0.001$ .

**Table 3. Event Rate and Relative Risk of 30-Day Mortality After Ischemic Stroke in Persons with and Without Type 2 Diabetes**

Variables	Year				Change		P-value linear trend
	2000-2004	2005-2009	2010-2014	2015-2018	Absolute change	Percent change	
	IR (95% CI)	IR (95% CI)	IR (95% CI)	IR (95% CI)			
30-day mortality							
No. of events/10,000 in T2D	4.73	2.56	1.70	0.79	-3.94	-83.24%	<0.0001
95% CI	(1.47, 11.28)	(0.44, 8.10)	(0.16, 6.74)	(0.01, 5.21)			
No. of events/10,000 in non-T2D	4.50	2.21	1.24	0.52	-3.98	-88.55%	<0.0001
95% CI	(1.35, 10.97)	(0.31, 7.55)	(0.06, 5.98)	(0.00, 4.70)			
RR (95%CI)	0.92(0.81, 1.05)	1.05(0.81, 1.38)	1.25(0.80, 1.96)	1.48(0.35, 6.25)			<0.0001

Sex							
Female							
No. of events/10,000 in T2D	4.65	2.37	1.10	0.61	-4.04	-86.85%	<0.0001
95% CI	(1.43, 11.17)	(0.37, 7.81)	(0.04, 5.74)	(0.00, 4.88)			
No. of events/10,000 in non-T2D	4.11	2.06	1.02	0.30	-3.81	-92.59%	<0.0001
95% CI	(1.15, 10.40)	(0.26, 7.32)	(0.03, 5.60)	(0.00, 4.30)			
RR (95%CI)	0.97(0.80, 1.17)	1.01(0.67, 1.53)	0.81(0.35, 1.90)	2.58(0.19, 35.64)			<0.0001
Male							
No. of events/10,000 in T2D	4.81	2.73	2.20	0.93	-3.88	-80.63%	<0.0001
95% CI	(1.52, 11.40)	(0.51, 8.36)	(0.31, 7.54)	(0.02, 5.45)			
No. of events/10,000 in non-T2D	4.90	2.34	1.42	0.67	-4.23	-86.33%	<0.0001
95% CI	(1.57, 11.53)	(0.36, 7.75)	(0.09, 6.28)	(0.00, 4.99)			





RR (95%CI)	0.90(0.75, 1.07)	1.07(0.76, 1.52)	1.45(0.85, 2.47)	1.20(0.21, 6.96)			<0.0001
Age, years							
<60							
No. of events/10,000 in T2D	2.35	1.01	0.66	0.63	-1.72	-73.34%	<0.0001
95% CI	(0.36, 7.77)	(0.03, 5.59)	(0.00, 4.97)	(0.00, 4.91)			
No. of events/10,000 in non-diabetes	1.40	0.60	0.26	0.62	-0.78	-55.60%	<0.0001
95% CI	(0.09, 6.26)	(0.00, 4.86)	(0.00, 4.21)	(0.00, 4.90)			
RR (95%CI)	1.61(1.27, 2.06)***	1.63(0.94, 2.80)	2.49(0.88, 7.03)	1.79(1.15, 3.50)			<0.0001
≥60							
No. of events/10,000 in T2D	9.77	5.99	3.80	1.08	-8.69	-88.94%	<0.0001
95% CI	(4.64, 18.09)	(2.20, 13.04)	(0.99, 9.95)	(0.03, 5.71)			
No. of events/10,000 in	12.34	5.85	3.21	1.36	-10.98	-89.01%	<0.0001

non-T2D							
95% CI	(6.45, 21.40)	(2.11, 12.85)	(0.71, 9.08)	(0.08, 6.18)			
RR (95% CI)	0.73(0.62, 0.85)***	0.90(0.66, 1.23)	1.04(0.63, 1.72)	1.11(0.23, 5.40)			<0.0001

T2D, type 2 diabetes; IR, incidence rate; RR, relative risk.

\*\*\*  $p < 0.001$ .





- Group
- Age <60 years
  - Age ≥60 years
  - Female
  - Male
  - Overall